Mammary Cell News Volume 7.48 | Dec 10 2015

ASXL2 Promotes Proliferation of Breast Cancer Cells by Linking ERα to Histone Methylation
The authors observed that additional sex comb-like 2 (ASXL2) interacts with ligand E2-bound estrogen receptor alpha (ERα) and mediates ERα activation. [Oncogene] Abstract

Reciprocal Regulation of ERα and ERβ Stability and Activity by Diptoindonesin G
Unlike ERα, ERβ has not been developed as a therapeutic target in breast cancer due to loss of ERβ in aggressive cancers. In a small-molecule library screen for ERβ stabilizers, the authors identified Diptoindonesin G (Dip G), which significantly increases ERβ protein stability while decreasing ERα protein levels. [Chem Biol] Abstract | Graphical Abstract

c-Met PET Imaging Detects Early Stage Loco-Regional Recurrence of Basal-Like Breast Cancer
The aim of this study was to assess [¹⁸F]AH113804,a peptide-based molecular imaging agent with high affinity for human c-Met, for the detection of early stage loco-regional recurrence in a human basal-like breast cancer model, HCC1954. [J Nucl Med] Abstract

Targeting Innate Immunity with dsRNA-Conjugated Mesoporous Silica Nanoparticles Promotes Anti-Tumor Effects on Breast Cancer Cells
The authors’ results showed that poly(I:C)-conjugated nanoparticles efficiently targeted breast cancer cells due to dsRNA/TLR3 interaction. [Chemistry] Abstract

The Isolation and Characterization of CTC Subsets Related to Breast Cancer Dormancy
Scientists identified proliferative and invasive properties of 3 dimensional circulating tumor cell (CTC) tumorspheres distinctive upon uPAR/int β1 combinatorial expression. [Sci Rep] Full Article

Down-Regulation of NDUFB9 Promotes Breast Cancer Cell Proliferation, Metastasis by Mediating Mitochondrial Metabolism
Scientists used quantitative proteomic analyses to compare a highly metastatic cancer cell line and a parental breast cancer cell line, and observed that NDUFB9, an accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (complex I), was down-regulated in highly metastatic breast cancer cells. [PLoS One] Full Article

Resveratrol Chemosensitizes HER-2-Overexpressing Breast Cancer Cells to Docetaxel Chemoresistance by Inhibiting Docetaxel-Mediated Activation of HER-2–Akt Axis
Researchers observed that introducing resveratrol as a chemosensitizer in docetaxel chemotherapy blocks upregulation and activation of HER-2 in addition to blocking downstream signaling pathways such as Akt. [Cell Death Discov] Full Article

CLINICAL RESEARCH

High XIST and Low 53BP1 Expression Predict Poor Outcome after High Dose Alkylating Chemotherapy in Patients with a BRCA1-Like Breast Cancer
The authors investigated whether XIST and 53BP1 expression predicted poor outcome of high dose (HD) chemotherapy within 28 BRCA1-like patients from a trial randomizing between HD or conventional chemotherapy, for which both XIST and 53BP1 status were available. [Mol Cancer Ther] Abstract

Deciphering Genomic Underpinnings of Quantitative MRI-Based Radiomic Phenotypes of Invasive Breast Carcinoma
Scientists found that transcriptional activities of various genetic pathways were positively associated with tumor size, blurred tumor margin, and irregular tumor shape and that miRNA expressions were associated with the tumor size and enhancement texture, but not with other types of radiomic phenotypes. [Sci Rep] Full Article

Association of BRCA1 Promoter Methylation with Sporadic Breast Cancers: Evidence from 40 Studies
Researchers observed the frequency of BRCA1 promoter methylation was statistically significantly higher in breast cancers than non-cancer controls. Furthermore, BRCA1 methylation was statistically associated with lymph node metastasis, histological grade 3, ER(-), PR(-), triple-negative phenotype, and decreased or lacking levels of BRCA1 protein expression. [Sci Rep] Full Article

Randomized Controlled Trial of Zoledronic Acid plus Chemotherapy versus Chemotherapy Alone as Neoadjuvant Treatment of HER2-Negative Primary Breast Cancer (JONIE Study)
A randomized controlled trial indicated that the rates of pathological complete response in the chemotherapy + zoledronic acid group was doubled to the chemotherapy group, though the additional efficacy of zoledronic acid was not demonstrated statistically. [PLoS One] Full Article

Visit our reviews page to see a complete list of reviews in the mammary cell research field.

Caris Life Sciences Research Yields New Molecular Insights into Rare Breast Cancers
Caris Life Sciences announced the presentation of data from two studies in which Caris Molecular Intelligence®, the company’s panomic, comprehensive tumor profiling service, was used to identify potentially targetable biomarkers in metaplastic breast carcinoma and malignant phyllodes tumors of the breast, two rare subtypes of breast cancer. [Press release from Caris Life Sciences discussing research to be presented at the 38^th Annual San Antonio Breast Cancer Symposium (SABCS), San Antonio] Press Release

Agendia’s MammaPrint and BluePrint Breast Cancer Tests to Be Highlighted at San Antonio Symposium
New breast cancer research highlighting the value of Agendia’s MammaPrint® and BluePrint® genomic tests will be presented in 10 scientific posters. Four of the posters will provide new findings from the NBRST trial, which encompasses results from more than 1,000 patients. [Press release from Agendia discussing research to be presented at the 38^th Annual San Antonio Breast Cancer Symposium (SABCS), San Antonio] Press Release

From our sponsor:
Learn about mucociliary differentiation of primary bronchial epithelial cells. Watch the video.

Lilly and Merck Expand Immuno-Oncology Collaboration Adding Abemaciclib and KEYTRUDA® Combination Trial
Eli Lilly and Company and Merck, announced another immuno-oncology collaboration that will evaluate abemaciclib, Lilly’s cyclin-dependent kinase (CDK) 4 and 6 inhibitor, and Merck’s KEYTRUDA® (pembrolizumab) in a Phase I study across multiple tumor types. Based on the Phase I trial results, the collaboration has the potential to progress to Phase II trials in patients who have been diagnosed with either metastatic breast cancer or non-small cell lung cancer. [Eli Lilly and Company] Press Release

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the mammary cell community.

NEW Post-Doctoral/PhD Researcher – Molecular Cancer Biology (University of Pennsylvania)

NEW Assistant Professor – Anatomic Pathology (University Hospitals Case Medical Center)

NEW PhD Researcher – Drug Resistance (University of Antwerp)

PhD Researcher – Personalized Immunotherapy for Cancer (ISPIC Consortium Members)

Postdoctoral Researcher – Cancer Immune Microenvironment (Cornell University)

Postdoctoral Researcher – HIF-Mediated Alternative Splicing in Cancer (ETH Zurich)

Postdoctoral Position – Epigenetics and Cancer (Moffitt Cancer Center)

Cancer Biologist – (Wake Forest Baptist School of Medicine)

Postdoctoral Research Fellow – Ovarian and Breast Cancer (Fred Hutchinson Cancer Research Center)

Academic Breast Pathologist – (Beth Israel Deaconess Medical Center)

Group Leader Position – Cancer Research (Oslo University Hospital)

Postdoctoral Research Fellow – Metastatic Breast Cancer (Fred Hutchinson Cancer Research Center)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.